Mutations in the glucocerebrosidase gene and Parkinson's disease in Ashkenazi Jews

New England Journal of Medicine

Volumn 351, Issue 19, 2004, Pages 1972-1977

  Aharon Peretz, Judith ^a,d   Rosenbaum, Hanna ^b,d   Gershoni Baruch, Ruth ^c,d  

^a Rambam Health Care Campus   (Israel)

^b Depts Hematol Bone Marrow T   (Israel)

^c RAMBAM MEDICAL CENTER   (Israel)

^d TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSYLCERAMIDASE;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; CONFIDENCE INTERVAL; CONTROLLED STUDY; FEMALE; GAUCHER DISEASE; GENE MUTATION; GENETIC ASSOCIATION; GENETIC PREDISPOSITION; GENETIC RISK; GENETIC SCREENING; HETEROZYGOSITY; HETEROZYGOTE; HETEROZYGOTE DETECTION; HUMAN; IDIOPATHIC DISEASE; JEW; MAJOR CLINICAL STUDY; MALE; PARKINSON DISEASE; PRIORITY JOURNAL; RECESSIVE INHERITANCE;

ALZHEIMER DISEASE; DNA MUTATIONAL ANALYSIS; FEMALE; GLUCOSYLCERAMIDASE; HETEROZYGOTE; HUMANS; JEWS; MALE; MUTATION; PARKINSON DISEASE; POLYMERASE CHAIN REACTION;

EID: 7444237665     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJMoa033277     Document Type: Article

References (30)

1. Gelb DJ, Oliver E, Gilman S. Diagnostic criteria for Parkinson disease. Arch Neurol 1999;56:33-9.
2. Lazzarini AM, Myers RH, Zimmerman TR Jr, et al. A clinical genetic study of Parkinson's disease: evidence for dominant transmission. Neurology 1994;44:499-506.
3. Payami H, Zareparsi S. Genetic epidemiology of Parkinson's disease. J Geriatr Psychiatry Neurol 1998;11:98-106.
4. Piccini P, Burn DJ, Ceravolo R, Maraganore D, Brooks DJ. The role of inheritance in sporadic Parkinson's disease: evidence from a longitudinal study of dopaminergic function in twins. Ann Neurol 1999;45:577-82.
5. Polymeropoulos MH, Lavedan C, Leroy E, et al. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 1997;276:2045-7.
6. Kitada T, Asakawa S, Hattori N, et al. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 1998;392:605-8.
7. Gorrell JM, DiMonte D, Graham D. The role of the environment in Parkinson's disease. Environ Health Perspect 1996;104:652-4.
8. Neudorfer O, Giladi N, Elstein D, et al. Occurrence of Parkinson's syndrome in type 1 Gaucher disease QJ Med 1996;89:691-4.
9. Machaczka M, Rucinska M, Skotnicki AB, Jurczak W. Parkinson's syndrome preceding clinical manifestation of Gaucher's disease. Am J Hematol 1999;61:216-7.
10. Tayebi N, Callahan M, Madike V, et al. Gaucher disease and parkinsonism: a phenotypic and genotypic characterization. Mol Genet Metab 2001;73:313-21.
11. Varkonyi J, Rosenbaum H, Baumann N, et al. Gaucher disease associated with parkinsonism: four further case reports. Am J Med Genet 2003;116A:348-51.
12. Bembi B, Zambito Marsala S, Sidransky E, et al. Gaucher's disease with Parkinson's disease: clinical and pathological aspects. Neurology 2003;61:99-101.
13. Grabowski GA. Gaucher disease: enzymology, genetics, and treatment. Adv Hum Genet 1993;21:377-441.
14. Horowitz M, Pasmanik-Chor M, Borochowitz Z, et al. Prevalence of glucocerebrosidase mutations in the Israeli Ashkenazi Jewish population. Hum Mutat 1998;12:240-4. [Erratum, Hum Mutat 1999;13:255.]
15. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992;55:181-4.
16. Diagnostic and statistical manual of mental disorders, 4th ed.: DSM-IV. Washington, D.C.: American Psychiatric Association, 1994.
17. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA work group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984;34:939-44.
18. Fahn S, Elton RL, Members of the Unified Parkinson's Disease Rating Scale Development Committee. Unified Parkinson's Disease Rating Scale. In: Fahn S, Marsden CD, Goldstein M, Calne DB, eds. Recent developments in Parkinson's disease. New York: Macmillan, 1987:153-63.
19. Beutler E, Gelbart T, West C. The facile detection of the nt 1226 mutation of glucocerebrosidase by 'mismatched' PCR. Clin Chim Acta 1990;194:161-6.
20. Nussbaum RL, Ellis CE. Alzheimer's disease and Parkinson's disease. N Engl J Med 2003;348:1356-64. [Erratum, N Engl J Med 2003;348:2588.]
21. Dauer W, Przedborski S. Parkinson's disease: mechanisms and models. Neuron 2003;39:889-909.
22. Bence NF, Sampat RM, Kopito RR. Impairment of the ubiquirin-proteasome system by protein aggregation. Science 2001;292:1552-5.
23. Yamao F. Ubiquitin system: selectivity and timing of protein destruction. J Biochem (Tokyo) 1999;125:223-9.
24. Leroy E, Boyer R, Auburger G, et al. The ubiquitin pathway in Parkinson's disease. Nature 1998;395:451-2.
25. Atsumi S, Nosaka C, Iinuma H, Umezawa K. Inhibition of glucocerebrosidase and induction of neural abnormality by cyclophellitol in mice. Arch Biochem Biophys 1992;297:362-7.
26. Lloyd-Evans E, Pelled D, Rjebeling C, et al. Glucosylceramide and glucosylsphingosine modulate calcium mobilization from brain microsomes via different mechanisms. J Biol Chem 2003;278:23594-9.
27. Brugg B, Michel PP, Agid Y, Ruberg M. Ceramide induces apoptosis in cultured mesencephalic neurons. J Neurochem 1996;66:733-9.
28. Orvisky E, Park JK, LaMarca ME, et al. Glucosylsphingosine accumulation in tissues from patients with Gaucher disease: correlation with phenotype and genotype. Mol Genet Metab 2002;76:262-70.
29. Wong K, Sidransky E, Verma A, et al. Neuropathology provides clues to the pathophysiology of Gaucher disease. Mol Genet Metab 2004;82:192-207.
30. Anca M, Paleacu D, Shabtai H, Giladi N. Cross-sectional study of the prevalence of Parkinson's disease in the Kibbutz movement in Israel. Neuroepidemiology 2002;21:50-5.